Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Massachusetts General Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Université de Nantes, Nantes Université, University of Colorado Cancer Center, Memorial Sloan Kettering Cancer Center, Genentech, University Hospital Schleswig-Holstein
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2890579217